Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Cathepsin B Inhibitors Ease Alzheimer's Symptoms by Blocking Amyloid Plaque Formation

By BiotechDaily International staff writers
Posted on 27 Mar 2014
Image: Micrograph showing amyloid-beta (brown) in senile plaques of the cerebral cortex (upper left of image) and cerebral blood vessels (right of image) with immunostaining (Photo courtesy of Wikimedia Commons).
Image: Micrograph showing amyloid-beta (brown) in senile plaques of the cerebral cortex (upper left of image) and cerebral blood vessels (right of image) with immunostaining (Photo courtesy of Wikimedia Commons).
Neurobiologists studying the molecular processes underlying Alzheimer's disease have identified the mechanism that explains how inhibition of cathepsin B activity blocks formation of the toxic amyloid-beta (Abeta) peptides that characterize the disease.

Cathepsin B was once suspected as being a protease participating in the conversion of beta-amyloid precursor protein into the amyloid plaques found in Alzheimer's disease patients. However, this function is now known to be mediated by BACE1 protease. It is now thought that cathepsin B can degrade beta-amyloid precursor protein into harmless fragments. Thus, it is conceivable cathepsin B may play a pivotal role in the natural defense against Alzheimer's disease.

However, new findings reported in the March 4, 2014, online edition of the Journal of Alzheimer’s Disease by investigators at the University of California, San Diego (USA) and colleagues at the biopharmaceutical company American Life Science Pharmaceuticals, Inc. (San Diego, CA, USA) have altered this concept by showing that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocked creation of key neurotoxic amyloid-beta peptides linked to Alzheimer’s disease.

Using various mouse models, the investigators showed that oral administration of E64d a cysteine protease inhibitor of cathepsin B, not only reduced the build-up of beta-amyloid in the brains of these animals, but it also caused substantial improvement in memory.

“This is an exciting finding,” said senior author Dr. Vivian Hook, professor of pharmaceutical sciences at the University of California, San Diego. “It addresses a new target—cathepsin B—and an effective, safe small molecule, E64d, to reduce the pGlu-Abeta that initiates development of the disease’s neurotoxicity. No other work in the field has addressed protease inhibition for reducing pGlu-Abeta of Alzheimer's disease.”

Related Links:

University of California, San Diego
American Life Science Pharmaceuticals, Inc.



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.